flanders.bio is an independent life sciences cluster organisation based in Flanders, Belgium

flanders.bio is a dynamic, member driven organisation with currently more than 350 members from Belgium and abroad. We help our members to create value by organising Networking and Training Activities, supporting Internationalisation, providing Services and building Expertise. flanders.bio and its members want to be the proud advocates of a reputable global-impact ecosystem in life sciences.

News from flanders.bio and its members

MDxHealth Notice of Financial Year 2017 Results

Conference call for analysts and investors to be held on 22 February 2018 at 15:00 CET

Finance | 15 February 18 Read more

Wereldrecord genoomanalyse dankzij Leuvense software

Wetenschappers van het Rady Children’s Institute for Genomic Medicine in San Diego (US) reduceerden de tijd nodig voor een diagnose van zeldzame genetische aandoeningen bij pasgeborenen tot minder dan een dag.

Patients | 13 February 18 Read more

Imec Introduces CMOS Chip With 16,384 Micro-electrodes and 1,024 Channels for Multimodal Cell Interfacing

Imec, the world-leading research and innovation hub in nanoelectronics and digital technologies, has designed and fabricated a 16,384-electrode, 1,024-channel micro-electrode array (MEA) for high-throughput multi-modal cell interfacing. The chip offers intracellular and extracellular recording, voltage- and current-controlled stimulation, impedance monitoring and spectroscopy functionalities thereby packing the most cell-interfacing modalities on a single chip, and being the only one to enable multi-well assays. With this new chip, imec has created a platform that enables high quality data acquisition at increased throughput in cell-based cell studies. Imec’s micro-electrode array chip will be presented at ISSCC in San Francisco, Feb. 11-15.

Research | 12 February 18 Read more

HDAC6 inhibitors protect against neuronal damage and have therapeutic potential in both neurology and oncology

Inhibiting HDAC6 improves the structural stability of cells and protects against neuronal damage. Leuven research uncovered that targeting this mechanism could be a promising therapeutic approach for peripheral neuropathies, whether due to Charcot-Marie-Tooth disease (CMT) or as a side effect of chemotherapy.

Research | 08 February 18 Read more

flanders.bio events, trainings & international missions

Strategic Partners